Tumor News and Research

RSS

Targeted nanoparticles enable in vivo production of CAR T cells for cancer therapy

Researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells.

20 Jun 2025

Transfer RNA-derived small RNAs transform the landscape of liquid biopsy

A new review highlights the transformative potential of transfer RNA-derived small RNAs (tsRNAs) in the field of liquid biopsy, emphasizing their role as promising biomarkers for a wide range of diseases, particularly cancers.

20 Jun 2025

Exploring the intricate epigenetic regulatory network of lncRNAs in hepatocellular carcinoma

A new review published in Genes & Diseases explores the intricate epigenetic regulatory network of long noncoding RNAs (lncRNAs) in hepatocellular carcinoma (HCC), shedding light on the profound impact of DNA methylation, histone modifications, RNA methylation, and microRNAs on lncRNA transcription.

20 Jun 2025

Inflammation and immune dysregulation drive breast cancer in aging women

Age-related and postmenopausal breast cancer progression remains a significant challenge, with growing evidence pointing to the role of pro-inflammatory cytokines and CXC chemokines in tumor development and immune system modulation.

20 Jun 2025

Targeting IGF2BP1 offers a new approach to cancer therapy

The RNA-binding protein IGF2BP1 has emerged as a key regulator of cancer hallmarks, influencing tumor proliferation, metastasis, immune evasion, and resistance to cell death.

20 Jun 2025

Circular RNAs emerge as key players in hepatitis B-related liver cancer

Hepatitis B virus-induced hepatocellular carcinoma (HCC) remains a major global health burden, and new therapeutic and diagnostic approaches are urgently needed.

20 Jun 2025

New 3D immunohistochemistry method enhances deep tissue imaging

Three dimensional immunohistochemistry (3D-IHC) has transformed our ability to visualize the spatial arrangement of cells and molecules in intact tissues.

19 Jun 2025

New technology tracks solid tumor treatment response through blood samples

Altum Sequencing, a start-up supported by the C3N-IA Science Park at Universidad Carlos III de Madrid (UC3M) and specialized in oncology, has developed a tool to monitor treatment response in patients with solid tumors from a simple blood sample.

19 Jun 2025

Epigenetic dysregulation drives hepatocellular carcinoma development

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and a leading cause of cancer-related deaths worldwide.

19 Jun 2025

Understanding the interconnected roles of microbial, metabolic, and immune biomarkers in IBD

Inflammatory Bowel Disease (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammatory condition of the gastrointestinal tract with a rising global burden.

19 Jun 2025

Full tumor DNA sequencing becomes standard for children with cancer

Readouts of the full DNA of children with cancer at diagnosis have been implemented as the standard of care in a European first.

19 Jun 2025

Inhibiting RNA Polymerase 1 suppresses tumor growth in hard-to-treat cancers

Researchers at the Johns Hopkins Kimmel Cancer Center and Department of Radiation Oncology and Molecular Radiation Sciences uncovered a new tumor-suppressive response that could lead to novel therapies targeting hard-to-treat cancers.

18 Jun 2025

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

18 Jun 2025

OCCAM Immune and Cancer Research Institute join forces to advance immunotherapy

In a new collaboration that could transform how cancer is treated, OCCAM Immune-a Mount Sinai initiative focused on understanding the immune system's role in disease-is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

17 Jun 2025

Rare pancreatic cancer patients show remarkable outcomes with immunotherapy

A new research paper was published in Volume 16 of Oncotarget on June 10, 2025, titled "Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence."

17 Jun 2025

Could a diabetes drug be the key to stopping Alzheimer’s?

Investigating tirzepatide's role in Alzheimer's reveals its potential to improve brain function and reduce inflammation, linking diabetes and neurodegeneration.

17 Jun 2025

Breakthrough therapy targets aggressive bladder cancer variant

Bladder tumors that have been excluded from clinical trials have a few things in common that could lead to new therapies.

17 Jun 2025

Researchers identify a new treatment strategy for neuroblastoma

Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer.

16 Jun 2025

‘Not accountable to anyone’: As insurers issue denials, some patients run out of options

By the time Eric Tennant was diagnosed in 2023 with a rare cancer of the bile ducts, the disease had spread to his bones. He weighed 97 pounds and wasn't expected to survive a year with stage 4 cancer.

16 Jun 2025

FDA approval of pembrolizumab marks major shift in head and neck cancer treatment

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test.

15 Jun 2025